• Some 50 PGA TOUR professionals now play Newton shafts, validating the company’s rapid growth and elite performance standards.
• Tour winners such as Miguel Ángel Jiménez, Doug Barron and Ken Duke credit Newton’s shafts for delivering superior control, distance and consistency.
• The Fast Motion shaft, Newton’s latest innovation, continues to gain momentum with lightweight precision performance and increasing Tour adoption.

Newton Golf Company (NASDAQ: NWTG) has hit a major milestone in its mission to redefine golf shaft performance — more than 50 professionals across the PGA TOUR Champions and LPGA Tour have now used Newton shafts in competition (https://ibn.fm/5Mcdq). This marks a significant leap from earlier in the season, reflecting growing trust from elite players who value precision, consistency and innovation.

One of Newton’s most impactful endorsements came when Ken Duke became the first professional to officially sign with the brand, integrating the Newton Motion shaft into his bag for the 2024 season (https://ibn.fm/Q9jDe). His standout performance, ranking no. 1 in driving accuracy at the Constellation FURYK & FRIENDS (https://ibn.fm/V2aFq), highlighted the shaft’s consistency and power. “It’s unbelievable how I can shape it,” Duke said. “Not only that, but I’ve gained 6–15 yards with it.”

Duke introduced the shaft to fellow PGA TOUR Champions standout Doug Barron, who then made headlines by winning the 2024 Regions Tradition, his first major title, using Newton Motion (https://ibn.fm/TW96N). Barron saw “tighter dispersion and five more yards” after switching, which gave him “the confidence to win my first major championship.”

Back-to-Back Wins for Jiménez Using Newton Fast Motion

In a further show of validation, Miguel Ángel Jiménez, one of the most accomplished players on the PGA TOUR Champions, signed with Newton earlier this year (https://ibn.fm/dOlWg) — and has since won four PGA TOUR Champions victories (https://ibn.fm/7JVjG). Last month, he won the Kaulig Companies Championship, rallying to force a playoff and winning with a 20-foot birdie putt on the second extra hole. 

Prior to that, he had come out on top at the Principal Charity Classic at the Wakonda Club, the Trophy Hassan II in Morocco and the Hoag Classic in Newport Beach, California 

Jiménez currently leads the PGA TOUR Champions money list (https://ibn.fm/iPmsf), demonstrating the Newton shaft’s impact at the top tier. “Amazing that my game is still nice.” Jimenez said. “I still have a good distance from the tee, my irons are good, they’re sharp, and then [I] still enjoy what I’m doing. That to me is perfect. The only thing is keep counting. I hope it’s not the last one.”

A Lighter, Faster Shaft Built for Control

The Fast Motion shaft — Newton’s newest innovation — is a lighter Tour-proven option built from advanced high-modulus Toray carbon fibers (https://ibn.fm/UOc1o). The shaft reduces weight by ~10 grams vs. the Motion series while maintaining elite control and tight dispersion. Designed for faster swing speeds, the Fast Motion loads naturally for consistent timing and more powerful strikes.

Golf Magazine’s Kris McCormack said it best: “When you start seeing some of the best ball strikers of the last 30 years slotting Newton shafts into the bag, that’s not noise — that’s a signal.”

Innovation Driving Market Success

In fiscal year 2024, Newton Golf reported 887% YoY revenue growth, driven by the success of its proprietary shafts (https://ibn.fm/93tGl). The company’s strategy includes:

• R&D focused on physics-first engineering
• Shafts manufactured in the U.S. for quality control and logistics advantage
• Direct-to-consumer and fitter-driven sales model
• Strong presence across PGA TOUR Champions and growing LPGA adoption.

With more than 50 Tour players trusting Newton shafts and recent victories reinforcing the brand’s performance, Newton Golf is quickly establishing itself as a premier force in the golf-equipment industry.

For more information, visit the company’s website at www.NewtonGolfIR.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

• Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis.
• The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial.
• IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging.
• A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones.
• Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility.

Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of breast cancer. Focused exclusively on this clinical area, Izotropic is developing purpose-built technologies designed to address persistent limitations in conventional breast imaging. Through innovation in both device architecture and image acquisition, the company aims to enhance diagnostic confidence while improving patient experience.

Izotropic’s mission is to deliver transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. By introducing a next-generation imaging platform for breast cancer screening and diagnosis, the company is targeting a clear unmet need in a multibillion-dollar global market. Its vision centers on redefining how breast imaging is performed—shifting away from adaptations of whole-body scanners or 2D mammography toward a fully dedicated approach optimized for breast anatomy.

The company’s strategy is built around a singular platform with expansion potential. Izotropic is focused on commercializing its lead product through a staged pathway that includes regulatory authorization, clinical validation, and strategic investor engagement. In parallel, the company is developing educational tools and communications platforms to raise awareness among patients, clinicians, and stakeholders about the evolving role of dedicated breast imaging technologies in cancer care.

The company is headquartered in Vancouver, British Columbia, with operations in Sacramento, California.

Technology Portfolio

Izotropic’s flagship product is the IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without compression. The IzoView system was advanced from academic innovation to commercial readiness by Izotropic’s in-house team, building on exclusively licensed technology developed at the University of California, Davis to optimize diagnostic accuracy, patient comfort, and clinical workflow. IzoView integrates proprietary mechanical design, patented hardware innovations, and trade-secret software algorithms, along with AI-driven enhancements designed to improve radiologist performance.

Now in clinical-ready form and housed at Izotropic’s engineering facility in Sacramento, California, IzoView was built under an ISO 13485-compliant quality management system. It is scheduled for use in the company’s planned U.S. clinical trial for FDA market authorization. The device is also central to the company’s broader commercialization strategy, which includes platform extensions and future imaging-based product lines outlined in its recently completed 150-page business plan and financial model.

In preparation for launch, Izotropic is also rolling out strategic awareness platforms. These include a company-hosted podcast and the development of breastct.com, a new educational resource to support patients, clinicians, and stakeholders. These initiatives are designed to enhance engagement, reinforce brand positioning, and build early market traction for IzoView.

Market Opportunity

Izotropic is targeting the global breast imaging market, which is undergoing rapid innovation as healthcare providers seek more accurate, patient-friendly alternatives to traditional mammography. Current screening technologies have well-documented limitations in detecting tumors in women with dense breast tissue, a challenge IzoView directly addresses.

According to a report by MarketsandMarkets, the breast imaging market is projected to grow from $4.3 billion in 2023 to $6.6 billion by 2028, at a compound annual growth rate (CAGR) of 8.9%. Key drivers include the increasing prevalence of breast cancer, the shift toward early detection, and advances in imaging technology such as AI integration and contrast-enhanced diagnostics.

Izotropic’s licensing structure with UC Davis allows the company to pursue either FDA or CE Mark approval, offering flexibility for U.S. and international market entry. Izotropic’s go-to-market plan is supported by ongoing education efforts and a structured clinical strategy, both aligned to accelerate adoption and unlock value in a growing global market.

Leadership Team

Robert Thast, Interim CEO, is the founding executive of Izotropic and has over 30 years of experience leading public companies. He has raised over $100 million in capital, built cross-functional leadership teams, and guided early-stage ventures through public listings and strategic transitions. At Izotropic, he oversees corporate development, financing, and market strategy.

Dr. John Boone, Ph.D., Principal Founder and Director, is a Distinguished Professor of Radiology and Biomedical Engineering at UC Davis. He is a pioneer in breast CT development, having built and tested four dedicated scanners and led trials with nearly 500 women. He has held top roles in AAPM and RSNA and currently serves as Editor-in-Chief of Medical Physics.

Ralph Proceviat, CPA, CFO and Director, brings more than four decades of experience in finance, restructuring, and cross-border operations. He has served as CEO, President, and CFO across multiple sectors and has raised significant capital for both public and private ventures. He is also the founder of C-Suite-Consulting.

Dr. Younes Achkire, Ph.D., Chief Operating Officer and Lead Engineer, is the technical lead behind IzoView. He previously co-founded Zap Surgical Systems and has commercialized FDA-cleared technologies in medtech and clean energy. At Izotropic, he manages engineering, manufacturing, clinical deployment, and operational scale-up.

For more information, visit the company’s website at https://izocorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

• The Dominion Creek property lies within a highly prospective ground underlain by the Isaac Lake Fault system.
• Nicola marked a major milestone at Dominion by obtaining the final bulk sample permit from BC authorities, allowing extraction of up to 10,000 tonnes of ore.
• Resource potential at Dominion Creek is supported by historic high-grade production. 

Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is steadily advancing its Dominion Creek project in British Columbia’s gold-rich region, integrating gold and silver exploration with nearby milling infrastructure to deliver both resource growth and early-stage production outcomes. The company’s focus on strategic permits, strong assay results and a vertically integrated model underscores its vision of becoming a reliable, cash-flow generating junior miner.

The Dominion Creek property, located 43 kilometers northeast of Wells, lies within a highly prospective ground underlain by the Isaac Lake Fault system (https://ibn.fm/kJ1VH). Nicola holds a 75% economic interest in the project through a combination of land ownership and profit-sharing agreements with High Range Exploration Ltd. The 7.5 km-long claim package hosts high-grade gold-silver veins, with historic sampling revealing standout grades, such as 62.1 g/t Au and 320 g/t Ag from a 9.7 kg surface sample, underscoring the area’s exploration potential (https://ibn.fm/JiVTT).   

In March, Nicola marked a major milestone with the Dominion Creek project by obtaining the final bulk sample permit from the BC government, which will allow Nicola to extract up to 10,000 tonnes of ore (https://ibn.fm/h4km5). A free-use permit accompanying this licence authorizes construction of haulage roads to support future mining activities. This regulatory win positions Nicola to initiate extraction at Dominion Creek, which is the next major step for the company. The company has funded road upgrades via a $50,000 investment to High Range, accelerating progress toward bulk sampling (https://ibn.fm/lvFrS). 

The company plans to transport the high-grade gold ore from the town of Wells to Nicola’s wholly owned Merritt Mill, a fully permitted custom processing facility capable of handling multiple gold-silver feed sources. This mill operation encourages Nicola’s self-sustaining balance sheet, generating cash flow while developing its copper, gold and silver projects. According to a recent Noble Research Report, the company expects Dominion Creek to contribute to the Merritt Mill’s ramp-up in Q3, complementing other ore sources such as Blue Lagoon’s Dome Mountain project (https://ibn.fm/6Vt0y). 

The potential upside at Dominion Creek is worth highlighting. It is supported by a historic 1,180-tonne bulk sample taken in 1992 from the South Zone, which delivered head-grade gold of approximately 14.1 g/t and gold recovery rates near 93% through conventional processing (https://ibn.fm/enaAB). Recent head samples from vein targets such as Number 16 have yielded up to 62.1 g/t Au and 320 g/t Ag, with similar high-grade results (e.g., 58.7 g/t Au, 130 g/t Ag) from concentrates produced in 1989–1992. These grades speak to the high-end potential of Dominion’s mineralization. The project also benefits from established infrastructure, First Nations engagement — including a letter of support from the Lheidli T’enneh — and a bulk-sample permitting process (https://ibn.fm/3LrH2). 

Nicola’s operational blueprint for 2025 includes commencing Dominion Creek’s bulk sample extraction in Q3, reaching and maintaining full-production capacity at the Merritt Mill, and publishing exploration results for the flagship New Craigmont (Copper) Project (https://ibn.fm/U71Qd). Nicola’s strategy synergizes with its broader corporate objectives: To concentrate operations within British Columbia. In tandem with Dominion Creek and New Craigmont, the company is advancing Treasure Mountain, a silver-lead-zinc project (https://ibn.fm/njFlN). The integration of exploration and processing capability enhances Nicola’s sustainability and operational efficiency, positioning itself for further organic growth.

Nicola Mining stands out among other junior miners, especially in BC. Its balanced strategy blends exploration upside with steady cash flow from processing ore. By capturing value from its high-grade gold-silver system, and converting it into tangible ore through a permitted mill, Nicola effectively minimizes dilution and enhances its appeal to investors seeking actionable exposure to resource development in British Columbia.

In summary, Nicola Mining’s Dominion Creek project is entering a new phase, transitioning from exploration to bulk sampling and production. Supported by records of historically high-grade samples, operational permits, and the Merritt Mill, Dominion Creek highlights Nicola’s growing impact on the BC’s mining sector.

For more information, visit www.NicolaMining.com.

NOTE TO INVESTORS: The latest news and updates relating to HUSIF are available in the company’s newsroom at https://ibn.fm/HUSIF 

• Platinum’s unique properties — exceptional conductivity, heat resistance and catalytic efficiency — make it indispensable across a range of electrical applications. 
• Hydrogen fuel cells, particularly the proton exchange membrane variety, are one of the most promising sources of green energy production.
• PLG is a player in this emerging landscape, with a focus on the development of large-scale platinum group metal resources in the Bushveld Complex.

As global industries search for scalable and sustainable energy solutions, platinum has emerged as a critical component in the future of electrical applications. Platinum Group Metals (NYSE American: PLG) (TSX: PTM), is well positioned to help meet this growing demand through its strategic operations in South Africa’s platinum-rich Bushveld Complex.

Platinum’s unique properties — exceptional conductivity, heat resistance and catalytic efficiency — make it indispensable across a range of industrial and electrical applications. From use in hard disk drives and thermocouples to spark plugs and oxygen sensors, platinum has long played a quiet but crucial role in technology and industry. However, the metal’s importance is rapidly evolving beyond conventional applications, thanks to the increasing demand for clean-energy solutions, particularly hydrogen fuel cells, which rely on platinum as a catalyst.

The growth of artificial intelligence has brought platinum into sharper focus as the world grapples with the energy demands of next-generation computing. A report by the Japan Exchange Group explains that training advanced AI models, such as ChatGPT, requires enormous power, with daily electricity consumption equivalent to that of 17,000 average U.S. households (https://ibn.fm/oY3Q1). This level of demand, especially when concentrated in large-scale data centers, presents serious environmental and sustainability challenges. As these AI models become more complex and integrated across industries, the pressure to reduce their carbon footprint is pushing the development of cleaner power alternatives.

One of the most promising of these alternatives is the hydrogen fuel cell, particularly the proton exchange membrane (“PEM”) variety that uses platinum to catalyze an electrochemical reaction between hydrogen and oxygen. Unlike traditional energy sources, hydrogen fuel cells do not rely on combustion and emit no carbon dioxide. Their only byproducts are water and heat (https://ibn.fm/V4Bvv). This makes them especially appealing as a stationary power source for energy-intensive data centers and AI operations. 

“Further, the hydrogen used by fuel cells can be produced through the electrolysis of water, powered by renewable energy sources such as wind and solar, making the energy provided completely fossil free,” reported the Japan Exchange Group. “The WPIC estimates that around a third of the global electrolyser market will rely upon platinum-containing PEM electrolysers.”

Platinum Group Metals is working to be a player in this emerging landscape. The company’s primary focus is the development of large-scale platinum group metal resources in the Bushveld Complex, a region responsible for producing roughly 75% of the world’s platinum supply (https://ibn.fm/VfthP). The company’s flagship project, the Waterberg Project, is one of the newest and largest undeveloped PGM resources in South Africa (https://ibn.fm/UCdzf). It is specifically designed to support low-cost, bulk mechanized mining, ideal for supplying high volumes of platinum to markets increasingly driven by technological and environmental innovation.

Waterberg is also notable for its high palladium content, another metal used in emissions control systems, as well as significant amounts of rhodium and gold. 

Platinum Group Metals continues to advance the Waterberg Project in partnership with leading industry players, including Impala Platinum Holdings Ltd., a major global PGM producer, Japan Organization for Metals and Energy Security and Hanwa Co., Ltd.  This joint venture provides PLG with technical and financial support as it moves toward development.  In addition, PLG and Valterra Platinum Limited are working together through joint venture corporation Lion Battery Technologies Inc. to develop next-generation lithium-sulphur battery technology that incorporates platinum and palladium into new cathode designs aimed at improving battery life, energy density and efficiency.

With rising global awareness around climate change, energy sustainability and the environmental cost of AI technologies, platinum’s relevance in clean, high-performance electrical systems is growing. Platinum Group Metals’ development activities place it at the heart of this transition, helping to supply a metal that is both critical to industry and environmentally beneficial.

For more information, visit www.PlatinumGroupMetals.net.  

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

• Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8^® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need.
• Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors.
• Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025.
• Clene is preparing to initiate a confirmatory Phase 3 ALS trial in the first half of 2026, with a separate MS (multiple sclerosis) program in late-stage development.

Investors looking for exposure to important biopharma innovation in underserved markets need to consider Clene (NASDAQ: CLNN). Clene and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is advancing its lead candidate CNM-Au8^®, a unique and needed oral treatment for ALS, toward a potential FDA accelerated approval. 

Clene’s primary value proposition lies in its differentiated mechanism of action and its potential to secure a meaningful share of the large and growing ALS treatment market. CNM-Au8 is a suspension of gold nanocrystals designed to enhance mitochondrial function and protect neurons, an approach that targets the bioenergetic deficits believed to underlie ALS as well as other neurodegenerative diseases. This could be just the beginning. 

The company’s next inflection point is expected in Q4 2025, when it will report neurofilament light chain (“NfL”) biomarker results from over 150 ALS patients treated in the NIH-sponsored Expanded Access Program (“EAP”). Positive results would strengthen Clene’s case for a New Drug Application (“NDA”) under the FDA’s accelerated approval pathway. According to Clene, the FDA has responded constructively and accepted the basis for the company’s revised statistical analysis plan, which was recently resubmitted for final approval (https://ibn.fm/9EM0s).

Benjamin Greenberg, MD, Clene’s Head of Medical, said the FDA’s “constructive feedback” encourages the company to move forward. The company has also scheduled two additional FDA meetings in 3Q 2025: one to discuss long-term survival data from the HEALEY ALS Platform Trial and another to evaluate Phase 2 results from its multiple sclerosis program.

From an investor perspective, these regulatory discussions could unlock significant value for Clene by accelerating CNM-Au8’s path to market. Based on positive NfL results, Clene plans to launch a confirmatory Phase 3 trial, RESTORE-ALS, in the first half of 2026.

The broader market opportunity is also compelling. According to Research and Markets, the global ALS market was valued at $791.90 million in 2024 and is projected to grow at a CAGR of 5.40%, to reach $1.3 billion by 2034, driven by the rising incidence of ALS and aging populations (https://ibn.fm/qmuTf) CNM-Au8, if approved, would be an important addition to only a few commercially available treatments for ALS.

Clene is also advancing a parallel MS program with the same CNM-Au8 drug asset. Clene will meet with FDA in Q3 2025 for its End-of-Phase 2 meeting, planned to pave the way for a Phase 3 trial targeting cognitive improvement in people with MS. Cognitive dysfunction significantly impacts people living with MS, remaining a key unmet need in the treatment of Multiple Sclerosis.

For investors, Clene’s value lies in its multiple shots on goal: regulatory catalysts in both ALS and MS, ongoing data generation, and a novel therapeutic platform. While clinical-stage biotechs carry inherent risks, the company’s unique approach could significantly shorten its path to commercialization and generate early revenue from a patient population with limited options.

Clene’s differentiated technology and advancing clinical programs position it as a company to watch with important investment potential in the evolving neurodegenerative therapy space.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Walker Lane holds global significance in the mining industry, known for producing more than 40 million ounces of gold, representing nearly 20% of Nevada’s total output
• Augusta Gold announced that AngloGold Ashanti has agreed to acquire the company for C$1.70 per share, valuing Augusta Gold at about C$152 million
• Lahontan Gold Corp. stands out in the Walker Lane region, not only for its robust land position, but also for the company’s focus on projects that blend historical production with scalable exploration and metallurgy

Walker Lane, a geologically rich corridor running along the California–Nevada border, has become a focal point for gold and silver exploration, drawing renewed attention from junior miners and major players alike. Among those at the forefront is Lahontan (TSX.V: LG) (OTCQB: LGCXF), a Canadian mineral exploration company advancing four premier gold and silver prospects in the region, capitalizing on both historic production and modern-day opportunity.

Walker Lane holds global significance in the mining industry, known for producing more than 40 million ounces of gold, representing nearly 20% of Nevada’s total output—and additional silver and copper byproducts (ibn.fm/nb147). Below this renewed investor and corporate interest lies growth in strategic land acquisitions, including the recent move by Augusta Gold.

Earlier this month, Augusta Gold announced that AngloGold Ashanti has agreed to acquire the company for C$1.70 per share, valuing Augusta Gold at about C$152 million, plus the repayment of stockholder loans (ibn.fm/bgC6D). This acquisition grants AngloGold access to Augusta’s Reward and Bullfrog projects in the Beatty District, some of the most promising parcels in the southern Walker Lane. Reward, poised for construction, already boasts proven and probable reserves totaling 370,000 ounces of gold and holds key permits needed to proceed (ibn.fm/D7QPz).

The Beatty District transaction underscores the broader resurgence taking place across Walker Lane. With political and regulatory support making Nevada a top-tier jurisdiction, as noted by the Fraser Institute—investors now view the corridor as a prime destination for gold development. Moreover, banking policy shifts, such as Basel III’s recognition of gold as a tier 1 liquid asset (ibn.fm/6byKl), bolster institutional interest in precious metals, enhancing appeal for Walker Lane assets 

Against this backdrop, Lahontan Gold Corp. stands out, not only for its robust land position, but also for the company’s focus on projects that blend historical production with scalable exploration and metallurgy. LGCFX’s flagship project is the Santa Fe Mine, a former producer in operation from 1988 to 1995, yielding 359,202 ounces of gold and 702,067 ounces of silver via open-pit heap leach. Santa Fe holds a NI 43-101 indicated resource of 1.539 million ounces of gold equivalent, with an additional 0.411 million ounces inferred.

Lahontan’s portfolio extends beyond Santa Fe to include West Santa Fe, Moho and Redlich — each offering distinct geology and upside potential. West Santa Fe lies just 13 km from the flagship site and features shallow, oxide-hosted gold-silver, with grab samples yielding up to 2.61 g/t Au and 899 g/t Ag (ibn.fm/SpqcY). The Moho project brings high-grade underground potential, while Redlich specializes in silver-rich mineralization, with historic estimates of 16.5 million ounces AgEq and new discoveries grading up to 17 g/t AgEq.

Recent news highlights Lahontan’s intensifying exploration efforts. The company has launched metallurgical testing at Santa Fe to refine heap-leach recovery and intends to update its Preliminary Economic Assessment, initially released in December 2024 and projecting a pretax NPV5 of $265 million and IRR of 41%. In addition, Lahontan plans to drill West Santa Fe in 2025 and build upon its 13,118 meters drilled across 50 holes since 2021.

Walker Lane’s infrastructure advantage, mining-friendly jurisdiction and underexplored vein potential make it fertile ground for Lahontan’s strategy. The company’s comprehensive approach from historically validated deposits to cutting-edge exploration, positions it to capitalize on the continuing momentum in Walker Lane. 

For more information, visit the company’s website at www.LahontanGoldCorp.com. 

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

• The United States saw a record-breaking 28.1 million on-course golfers in 2024, marking the seventh consecutive year of growth.
• The company’s Newton Motion Shaft, launched in late 2023, has become a go-to choice across the PGA TOUR Champions and LPGA Tour—with over 50 professionals putting it into play.
• Newton reported 246% year-over-year revenue growth in Q1 2025, driven by surging demand for its shaft technology and growing retail traction.

As summer 2025 gets underway, all signs point to a breakout season for the golf industry. Fueled by strong consumer demand, demographic expansion and increased innovation, golf is expected to lead outdoor retail growth in both participation and equipment sales, and innovative companies such as Newton Golf Company (NASDAQ: NWTG) are positioned to be leaders in the space.

According to the National Golf Foundation (“NGF”), the United States saw a record-breaking 28.1 million on-course golfers in 2024, marking the seventh consecutive year of growth and the largest single-year increase since 2000 (https://ibn.fm/UAyrn). In addition, the number of rounds played surged to 545 million, setting another all-time high and showcasing the sport’s continued momentum (https://ibn.fm/oqzoe).

What’s driving this boom? A powerful mix of millennial spending, tech-savvy newcomers and lifestyle appeal. The 18–34 age group is now the largest golfing demographic, with 6.8 million participants in 2024 (https://ibn.fm/oqzoe), and the average millennial golfer is projected to spend over $4,500 annually on golf-related purchases in 2025, more than any other age group (https://ibn.fm/TjvZz).

The global golf equipment market is on track to expand from $29.03 billion in 2024 to $30.41 billion in 2025, growing at a 4.8% compound annual growth rate (https://ibn.fm/CFUue). Specialty categories, such as custom shafts and premium putters, are among the fastest-growing segments, as seasoned players invest in performance upgrades and new golfers seek accessible, game-improving gear.

Against this backdrop of unprecedented growth, Newton Golf is emerging as a brand that both reflects and accelerates the industry’s evolution. Known for its precision-engineered shafts and patented putter technologies, Newton Golf is redefining modern golf performance.

The company’s Newton Motion Shaft, launched in late 2023, has become a favorite shaft on Tour Champions (https://ibn.fm/3i0mo). In part, this popularity is due to the shaft’s proprietary DOT System(TM), a flex redefinition that adapts to player swing speed for improved accuracy and distance (https://ibn.fm/KoD4u). Meanwhile, the Gravity Putter, introduced in fall 2024, features Ultra Low Balance Point (“ULBP”) technology for elite putting control and tighter roll dispersion (https://ibn.fm/9U4UQ).

With a U.S.-based manufacturing hub in St. Joseph, Missouri, Newton Golf maintains elite quality standards, faster lead times and supply chain resilience. The company’s direct-to-consumer strategy, bolstered by digital marketing and a growing network of club fitters, gives it a unique edge in converting rising interest into sales.

As the summer golf season heats up and more players hit the fairways, Newton Golf is positioned to not just follow the market’s growth but help lead it. The company is well placed to capture opportunity in a $30 billion and growing global golf-equipment market, while continuing to push the boundaries of performance and innovation.

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

• Middle-market companies do not have a great agency partner or solution that brings together essential services for them, notes CEO Claude Zdanow
• ONAR owns two different agencies that operate in the ecommerce and healthcare space; the company is also in the process of buying additional agencies
• The company charges per managed platform, such as Google, Facebook, Snapchat, etc., with unlimited creative and unlimited ad spend

The latest episode of the TechMediaWire Podcast delivers a compelling conversation with Claude Zdanow, CEO of ONAR Holding Corp. (OTCQB: ONAR), who discusses the company’s mission to empower middle-market firms with AI-driven marketing solutions (ibn.fm/luLHv). ONAR is a leading marketing technology company and agency network serving clients worldwide under Zdanow’s leadership.

During the interview, Zdanow provided deep insight into ONAR’s strategic business model, noting that ONAR owns and operates businesses that help middle-market companies generate revenue online. Specifically, Zdanow explained, ONAR owns two different agencies that operate in the ecommerce and healthcare space; the company is also in the process of buying additional agencies. 

 “With more and more ad platforms coming into the market every single day, middle market companies do not have a great agency partner or solution that can kind of bring that all together for them. So we’re doing that for both healthcare and ecommerce.”

ONAR is looking to dive deeper into both of those verticals, said Zdanow, as well as evaluating other sectors that provide potential. “Specifically, we’re looking for highly specialized tech-enabled agencies,” he said. “Everyone is talking about AI. . . obviously we’re using AI, and we have some interesting proprietary tech that helps us really give enterprise solutions to the middle market clients that we work with, or growth brands, we like to say.

“But the agencies that we’re looking to buy, we want the agencies that are really highly specialized and on the smaller scale,” he continued, “and that are doing one thing really, really well and ideally have something that is helping them, or they are using AI in a way to deliver better performance. Because everything we do is about generating revenue for our customers.”

Zdanow observed that ONAR’s model is a little different. “Our big differentiators are more like a SaaS platform,” he explained, noting that the company charges per managed platform, such as Google, Facebook, Snapchat, etc., with unlimited creative and unlimited ad spend. “We have a fixed startup fee for the initial platform, the first one we’re working with, and then we have an incremental fee for every additional platform you add, and we advertise currently on 22 different platforms…

“Our big differentiator is our technology and the way we are able to bring data together,” he continues. “If you’re a CEO of a middle-market company, you have the ability to basically have a trusted partner that can manage all those platforms for you and give you a kind of dashboard review in one single space for a fixed fee that doesn’t increase when you spend more ad spend, so we’re totally aligned with your success. . . .We saw the opportunity to turn the model on its head and bring SaaS and agency together with technology to deliver something that really was aligned with the incentives of these growth-stage companies.” 

Currently the company operates in two sectors that “we know aren’t going away — ecommerce and healthcare,” said Zdanow.  “People are always going to be buying stuff online in the digital ecosystem for the foreseeable future, and people are obviously going to be in the healthcare sector forever… So we’re just trying to build solutions and deliver agencies that serve both those areas, with a focus on performance, which is in our mind, generating revenue for the customers and for those businesses that we work with.”

ONAR currently operates across four agencies: Storia (performance marketing and SEO), Of Kos (healthcare marketing), CHALK (experiential marketing and events) and ONAR Labs (a technology incubator). Built on a foundation of “honor, candor, and best-in-class results,” ONAR serves businesses from mid-tier to growth-stage, spanning revenue brackets from approximately $50 million to more than $1 billion. 

ONAR is also active on the acquisition front, seeking to expand its network of specialized marketing operations. Combined with its AI focus and industrial coverage, acquisition growth positions ONAR to capitalize on rising demand for measurable, results-oriented marketing 

For more information, visit the company’s website at https://www.onar.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR Holding Corp. are available in the company’s newsroom at https://ibn.fm/ONAR

• The company’s shift from engineering/construction to asset ownership is central to the company’s long-term revenue growth plan.
• The acquisition of Solar Flow adds 70 contracted solar assets to SolarBank’s portfolio.
• The change in U.S. and Canadian energy policy provides a favorable regulatory environment, and $100 million financing from CIM Group supports 97 MW of U.S.-based solar development.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., announces that research firm D. Boral Capital has initiated coverage on the company.

These details are provided for information purposes only — SolarBank does not distribute research reports — and investors wishing to receive copies of the reports may contact the research analysts directly: Jesse Sobelson, CFA; jsobelson@dboralcapital.com; (929) 528-0985.

SolarBank, which develops and manages solar photovoltaic and battery storage projects, sells clean electricity to a range of customers including utilities, municipalities, commercial entities, and residential clients. With $190 million in total assets and a diversified pipeline, the company appears well capitalized for its next phase of expansion.

U.S. regulatory changes are also contributing to SolarBank’s momentum. The recently enacted “Big Beautiful Bill” provides full investment tax credits (“ITCs”) for solar and battery energy storage projects that will begin construction before July 4, 2026, and reach commercial operation within four years. This policy change introduces a defined timeline that may spur accelerated development across the sector. CEO Dr. Richard Lu noted that SolarBank has sufficient advanced-stage projects in its U.S. portfolio to begin construction before the ITC deadline.

Moreover, SolarBank recently announced a $100 million project-level financing arrangement with CIM Group. This funding will enable construction across its 97-MW U.S. project portfolio, which is concentrated in states where the company already holds project sites and has completed key permitting and interconnection milestones.

While scaling in the U.S., SolarBank is also maintaining a strong presence in Canada. In Ontario, the company is developing battery storage projects under the IESO’s Long-Term Request for Proposals (“RFP”) program. The initiative offers developers 10-year contracts for clean, dispatchable power, creating longer-term revenue predictability. In Nova Scotia, SolarBank participates in the Community Solar program, where it holds a substantial share of current and pending capacity.

Dr. Lu also pointed to Canadian infrastructure goals under Prime Minister Mark Carney’s recently launched “Build, baby, build” strategy, which emphasizes investments in clean energy, housing, and national infrastructure. “SolarBank benefits from Canada’s support to clean energy and is leading the charge to build Canada as an energy superpower,” he said.

For more information, visit the company’s website at SolarBankCorp.com.

This report contains forward looking information. Please refer to the press release entitled “SolarBank Issues Update on Strategic Positioning Amid Shifting U.S. and Canadian Policy Landscape” for additional details on the statements, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, substantially lowering quality of life. 
• Soligenix has taken on this challenge with SGX942, a treatment aimed at reducing tissue inflammation, promoting healing and supporting immune response. 
• The company is in the process of analyzing combined phase 2 and 3 datasets to design a second phase 3 study.

Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed at alleviating this condition, with promising phase 3 data showing substantial improvements in the duration and severity of mucositis in head and neck cancer patients™.

Oral mucositis occurs when chemotherapy or radiation damages the mucous membranes of the mouth, leading to painful ulcers, inflammation and impaired oral function. It is exceptionally common among patients receiving head and neck cancer treatments: nearly all experience some degree of mucositis, with 62.5–94% developing severe cases that can interfere with essential activities such as eating and speaking (https://ibn.fm/jYTW2).

Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, lowering quality of life substantially (https://ibn.fm/z8OeT). Because of these risks, effective treatment or prevention is critical to ensuring cancer therapies remain on schedule and patients maintain nutrition and comfort.

Statistics make the urgency palpable. A meta-analysis reveals that 94% of head and neck cancer patients undergoing radiotherapy develop oral mucositis, while 37% face severe cases (https://ibn.fm/DDsnI). One large institutional study reported that 98.6% of patients suffered mucositis, and 62.5% became severe, with nearly half struggling to swallow and over 50% requiring opiates by treatment end (https://ibn.fm/qJX2K).

Hallmarks of severe mucositis include weight loss, infections, hospitalization and delays in cancer treatment—all factors that can worsen patient outcomes. High-quality care must therefore include strategies to prevent or lessen mucositis to both preserve quality of life and optimize cancer therapy effectiveness.

Soligenix has taken on this challenge with SGX942 (dusquetide), an innate defense regulator aimed at reducing tissue inflammation, promoting healing and supporting immune response (https://ibn.fm/le0KI). The company’s phase 2 SGX942 clinical trial demonstrated remarkable results: a dose of 1.5 mg/kg demonstrated positive improvements in decreasing the duration of severe oral mucositis by 50% overall compared to the placebo group, from 18 days to 9 days (p=0.099). In patients at highest risk of oral mucositis (e.g., those exposed to the most aggressive concomitant chemotherapy), the reduction in the duration of severe oral mucositis was even more significant at 67% when treated with SGX942 1.5 mg/kg, from 30 days to 10 days (p=0.04). Secondary outcomes pointed to reduced infections, improved tumor resolution and enhanced survival among treated patients. 

These outcomes prompted advancement to a phase 3 clinical trial (referred to as the DOM-INNATE study), which enrolled 268 patients, 266 of which were included in the intent-to-treat (“ITT”) population. The ITT population included all patients who received at least one dose of study drug (https://ibn.fm/JUUj8). According to study results, the primary endpoint of median duration of SOM did not achieve statistical significance (p≤0.05), although biologic efficacy was observed with a 56% reduction in the median duration of SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group. 

“Other secondary endpoints supported the biologic efficacy of dusquetide as well, including a statistically significant 50% reduction in the duration of SOM in the per-protocol (“PP”) population, which decreased from 18 days in the placebo group to 9 days in the SGX942 treatment group (p=0.049), consistent with the findings in the Phase 2 trial,” the company noted. “Both ITT and PP populations saw clinically meaningful changes. The time for which the patients experienced severe oral mucositis was reduced by approximately 50%. The changes in the PP population were statistically significant.”

With phase 3 results being consistent with phase 2 results, particularly in terms of the decrease in duration of oral mucositis, Soligenix is in the process of analyzing the combined phase 2 and 3 datasets to design a second pivotal phase 3 study. The company is also in the process of identifying potential partners to continue this development program. 

Beyond SGX942, Soligenix is pursuing a broader strategy to tackle severe adverse effects of cancer therapy and dysregulated immune responses, using its innate defense regulatory platform to address mucosal injuries and inflammation across diverse patient populations. 

Oral mucositis stands as one of the most distressing side effects of cancer treatment, disrupting therapy, diminishing quality of life and demanding costly supportive care. Through SGX942 and led by experienced clinical leadership, Soligenix is advancing a promising candidate to change that landscape. 

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX